Search Result

Results for "

CCR2 antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CCR (32) HIV (3)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Endocrinology (23) Infection (4) Inflammation/Immunology (22) Metabolic Disease (3) Neurological Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101264

CCR2 antagonist 3	CCR	Inflammation/Immunology Endocrinology
CCR2 antagonist 3 is a chemokine receptor 2 *(CCR2)* antagonist.

HY-112792

CCR2 antagonist 1 1 Publications Verification	CCR	Endocrinology
CCR2 antagonist 1 is a high-affinity and long-residence-time *CCR2* antagonist, with a K_i of 2.4 nM.

HY-108323

CCR2 antagonist 4 3 Publications Verification Teijin compound 1	CCR	Inflammation/Immunology
CCR2 antagonist 4 (Teijin compound 1) is a potent and specific *CCR2* antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-103362

CCR2 antagonist 4 hydrochloride 3 Publications Verification Teijin compound 1 hydrochloride	CCR	Inflammation/Immunology
CCR2 antagonist 4 hydrochloride (Teijin compound 1 hydrochloride) is a potent and specific *CCR2* antagonist, with IC₅₀s of 180 nM for CCR2b. CCR2 antagonist 4 hydrochloride potently inhibits MCP-1-induced chemotaxis with an IC₅₀ of 24 nM .

HY-13499

JNJ-41443532 CCR2 antagonist 5	CCR	Inflammation/Immunology
JNJ-41443532 (CCR2 antagonist 5) is a selective, orally active hCCR2 inhibitor with good binding affinity (IC₅₀=37 nM) and potent functional antagonism (chemotaxis IC₅₀=30 nM). JNJ-41443532 displays a K_i of 9.6 µM for mCCR2 binding. JNJ-41443532 can be used in the research of inflammatory disease .

HY-112792A

*(1S)-CCR2* antagonist 1**	CCR	Endocrinology
(1S)-CCR2 antagonist 1 is a left-handed chiral body of CCR2 antagonist 1 (HY-112792). CCR2 antagonist 1 is a high-affinity and long-residence-time *CCR2* antagonist, with a K_i of 2.4 nM .

HY-50669

MK-0812	CCR	Inflammation/Immunology Endocrinology
MK-0812 is a potent and selective *CCR2* antagonist with low nM affinity for CCR2.

HY-50669A

MK-0812 Succinate	CCR	Inflammation/Immunology Endocrinology
MK-0812 Succinate is a potent and selective *CCR2* antagonist with high affinity at CCR2.

HY-50081

CCR2-RA-[R] 4 Publications Verification	CCR	Inflammation/Immunology Endocrinology
CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC₅₀ of 103 nM.

HY-108432

BMS-741672	CCR	Inflammation/Immunology
BMS-741672 is a selective and orally active *CCR2* antagonist with an IC₅₀ of 1.1 nM. BMS-741672 shows >700-fold selective for CCR2 than CCR5 .

HY-13245

PF-4136309 2 Publications Verification INCB8761	CCR	Inflammation/Immunology Endocrinology
PF-4136309 is a potent, selective, and orally bioavailable *CCR2* antagonist, with IC₅₀s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

HY-15418

RS 504393 15+ Cited Publications	CCR	Inflammation/Immunology Endocrinology
RS 504393 is a selective *CCR2* chemokine receptor antagonist (IC₅₀ values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).

HY-115874

BMS-753426	CCR	Others
BMS-753426 is a potent and orally bioavailable antagonist of *CCR2*.

HY-101713

Ilacirnon 1 Publications Verification CCX140; CCX140-B	CCR	Metabolic Disease Endocrinology
CCX140 (CCX140-B) is a potent *CCR2* antagonist.

HY-13245B

(Rac)-PF-4136309 (Rac)-INCB8761	CCR	Inflammation/Immunology
(Rac)-PF-4136309 is an isoform of PF-4136309 (HY-13245), which is a potent, selective, and orally bioavailable *CCR2* antagonist, with IC₅₀s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

HY-18611

RS102895 hydrochloride 15+ Cited Publications	CCR	Neurological Disease Endocrinology
RS102895 hydrochloride is a potent *CCR2* antagonist, with an IC₅₀ of 360 nM, and shows no effect on CCR1.

HY-18611A

RS102895 15+ Cited Publications	CCR	Neurological Disease Endocrinology
RS102895 is a potent *CCR2* antagonist, with an IC₅₀ of 360 nM, and shows no effect on CCR1.

HY-110132

JNJ-27141491	CCR	Inflammation/Immunology
JNJ-27141491 is a selective, noncompetitive and orally active functional antagonist of human *CCR2* .

HY-101908

BMS CCR2 22	CCR	Inflammation/Immunology Endocrinology
BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist with excellent binding affinity (binding IC₅₀ of 5.1 nM) and potent functional antagonism (calcium flux IC₅₀ of 18 nM and chemotaxis IC₅₀ of 1 nM) .

HY-109593

BMS-813160 1 Publications Verification	CCR	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
BMS-813160 is a potent and selective *CCR2/5* dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC₅₀s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation .

HY-13245A

(s)-PF-4136309 (s)-INCB8761	Others	Inflammation/Immunology Endocrinology
(s)-PF-4136309 is the isomer of PF-4136309 (HY-13245), and can be used as an experimental control. PF-4136309 is a potent, selective, and orally bioavailable *CCR2* antagonist, with IC₅₀s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

HY-117621

PF-04634817	CCR	Metabolic Disease
PF-0463481 is a potent and orally active dual *CCR2/CCR5* antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-117621A

PF-04634817 succinate	CCR	Metabolic Disease
PF-0463481 succinate is a potent and orally active dual *CCR2/CCR5* antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-14882A

Cenicriviroc Mesylate 5+ Cited Publications TAK-652 Mesylate; TBR-652 Mesylate	CCR HIV	Infection Inflammation/Immunology Endocrinology
Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual *CCR2/CCR5* antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

HY-14882

Cenicriviroc 5+ Cited Publications TAK-652; TBR-652	CCR HIV	Infection Endocrinology
Cenicriviroc (TAK-652) is an orally active, dual *CCR2/CCR5* antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity .

HY-12080

BX471 10+ Cited Publications ZK-811752	CCR	Inflammation/Immunology Endocrinology
BX471 (ZK-811752) is an orally active, potent and selective non-peptide *CCR1* antagonist with a K_i of 1 nM, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

HY-12080A

BX471 hydrochloride 10+ Cited Publications ZK-811752 hydrochloride	CCR	Inflammation/Immunology Endocrinology
BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide *CCR1* antagonist with K_i of 1 nM for human CCR1, and exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4.

HY-15450A

INCB 3284 2 Publications Verification	CCR	Endocrinology
INCB 3284 is a potent, selective and orally bioavailable human *CCR2* antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC₅₀ of 3.7 nM. INCB 3284 can be used in the research of acute liver failure.

HY-50674

INCB3344 Maximum Cited Publications 20 Publications Verification	CCR	Inflammation/Immunology Endocrinology
INCB3344 is a potent, selective and orally bioavailable *CCR2* antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

HY-15450

INCB 3284 dimesylate	CCR	Endocrinology
INCB 3284 dimesylate is a potent, selective and orally bioavailable human *CCR2* antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC₅₀ of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.

HY-50674A

INCB3344 R-isomer	CCR	Inflammation/Immunology
INCB3344 R-isomer is the R-isomer of INCB3344. INCB3344 is a potent, selective and orally bioavailable *CCR2* antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity .

HY-77111

cis-INCB3344	Others	Inflammation/Immunology Endocrinology
cis-INCB3344 is the isomer of INCB3344 (HY-50674), and can be used as an experimental control. INCB3344 is a potent, selective and orally bioavailable *CCR2* antagonist with IC₅₀ values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.

HY-103360

J-113863 3 Publications Verification	CCR	Inflammation/Immunology
J-113863 is a potent and selective *CCR1* antagonist with IC₅₀ values of 0.9 nM and 5.8 nM for human and mouse *CCR1* receptors, respectively. J-113863 is also a potent antagonist of the human *CCR3* (IC₅₀ of 0.58 nM) , but a weak antagonist of the mouse *CCR3* (IC₅₀ of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .

HY-N8501

Emestrin	Others	Infection
Emestrin is a mycotoxin originally isolated from E. striata that has antimicrobial, immunomodulatory, and cytotoxic activities. It is active against the fungi C. albicans and C. neoformans, as well as the bacteria E. coli, S. aureus, and methicillin-resistant S. aureus (MRSA; IC₅₀s=3.94, 0.6, 2.21, 4.55, and 2.21 μg/mL, respectively).2 Emestrin is a chemokine (C-C motif) receptor 2 (CCR2) antagonist (IC₅₀=5.4 μM in a radioligand binding assay using isolated human monocytes).3 Emestrin (0.1 μg/mL) induces apoptosis in HL-60 cells. It induces heart, thymus, and liver tissue necrosis in mice when administered at doses ranging from 18 to 30 mg/kg.

HY-19974

TAK-220 2 Publications Verification	CCR HIV	Infection Endocrinology
TAK-220 is a selective and orally bioavailable *CCR5* antagonist, with IC₅₀s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC₅₀s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC₉₀s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CCR2 antagonist

Inhibitors & Agonists